Redeye: Episurf Medical Q3 - Broadening customer base, but slower sales

2022-11-18 09:29:00

Redeye reiterates its fair value range for Episurf Medical following the Q3 report. While sales came in lower than we expected, we emphasise the early stage the company is in and argue that its customer base growth is currently a more relevant metric.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.